Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Stopped early · Phase 1

Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy consisting of gemcitabine and topotecan in treating patients with refractory or recurrent ovarian or fallopian tube cancer.

Key facts

Study ID

NCT00003382

Run by

Gynecologic Oncology Group

Starts

1998-05-01

Last updated by the study team

2013-06-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Community Hospital of Los Gatos — Los Gatos, California, United States
• Chao Family Comprehensive Cancer Center — Orange, California, United States
• Women's Cancer Center — Palo Alto, California, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Holden Comprehensive Cancer Center at The University of Iowa — Iowa City, Iowa, United States
• University of Pennsylvania Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.